A Phase Ib/II Clinical Study Of Bbi608 (Napabucasin) In Combination With Sorafenib Or Bbi503 (Amcasertib) In Combination With Sorafenib In Adult Patie
Posted Date: May 15, 2019
- Investigator: Olugbenga Olowokure
- Type of Study: Drug
Boston Biomedical BBI608-503-103HCC
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have Advanced Liver Cancer (Hepatocellula
Keywords:
Bbi608-503-103Hcc, Cancer, Gastrointestinal, Liver, Phase Ib/Ii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com